SCHEMBL19686892

SCHEMBL19686892

COc1cc(NC2CCC(F)(F)CC2)nc(-n2nc(C)cc2C)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.57
KCNN3 Q9UGI6 1/20 0.57
NPSR1 Q6W5P4 6/20 0.42
LMNA P02545 4/20 0.42
HIF1A Q16665 1/20 0.42
ALOX15 P16050 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 2/20 0.41
ADORA2A P29274 5/20 0.41
ADORA1 P30542 3/20 0.41
MAPT P10636 3/20 0.39
POLB P06746 3/20 0.39
MAPK1 P28482 3/20 0.39
NR2F2 P24468 2/20 0.39
TP53 P04637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PPP1CA P62136 2/20 0.39
NPC1 O15118 1/20 0.39
S1PR2 O95136 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20444097 0.93 KCNN2 (0.56) KCNN2KCNN3NPSR1LMNAHIF1A
SCHEMBL19687413 0.89 KCNN2 (0.55) KCNN2KCNN3NPSR1LMNAALOX15
SCHEMBL31127314 0.89 KCNN2 (0.55) KCNN2KCNN3NPSR1LMNAALOX15
SCHEMBL19686434 0.89 KCNN2 (0.53) KCNN2KCNN3NPSR1LMNAHIF1A
SCHEMBL19686948 0.89 KCNN2 (0.54) KCNN2KCNN3NPSR1LMNAHIF1A
SCHEMBL19686804 0.88 KCNN3 (0.73) KCNN2KCNN3NPSR1LMNAHIF1A
SCHEMBL21165969 0.87 KCNN2 (0.59) KCNN2KCNN3NPSR1LMNAHIF1A
SCHEMBL21165965 0.86 KCNN2 (0.76) KCNN2KCNN3NPSR1LMNAHIF1A
SCHEMBL19686521 0.84 KCNN3 (0.59) KCNN2KCNN3NPSR1LMNAALOX15
SCHEMBL19686601 0.84 KCNN2 (0.54) KCNN2KCNN3NPSR1LMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
CN-110198935-B Potassium channel modulators 卡登特治疗公司 2022-05-31 CN disclosed
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 US disclosed
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 US disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 EP disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 EP disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-10351553-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2019-07-16 US disclosed
US-10351553-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2019-07-16 US disclosed
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2018-08-02 US disclosed
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2018-08-02 US disclosed
WO-2018136917-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. (US) 2018-07-26 WO disclosed
WO-2018136917-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. (US) 2018-07-26 WO disclosed
US-9975886-B1 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975886-B1 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885NPSR1 993/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885NPSR1 993/4885
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 KCNN2 7/4885KCNN3 13/4885NPSR1 1560/4885
US-10717728-B2 Potassium channel modulators KCNJ2, KCNQ2, KCNJ1 KCNN2 7/4885KCNN3 22/4885NPSR1 1324/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885NPSR1 993/4885
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 KCNN2 7/4885KCNN3 13/4885NPSR1 1560/4885
US-10351553-B2 Potassium channel modulators KCNN2, KCNN1, KCNN3 KCNN2 1/4885KCNN3 3/4885NPSR1 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.